Why is CVS changing its CFO, and is this a sign of financial trouble?

The filing does not give a reason for the change beyond a planned transition. CEO David Joyner praised Cowhey's leadership, and the company's statement on 2025 results (meeting or exceeding guidance based on year-to-date results) does not suggest distress. Still, investors may want to watch how the handover affects the timing and tone of financial reporting.

What is Brian Newman's background and why does it matter?

Newman was CFO of UPS from September 2019 to May 2024 and spent 26 years at PepsiCo in finance, strategy, business development, and global operations roles, including chief strategy officer. His experience running a large, complex global company's finances is relevant to CVS's scale and its push to deliver better health care outcomes. He also sits on the board and audit committee of Colgate-Palmolive.

How does Newman's compensation compare to the outgoing structure, and what incentives does it create?

The package includes a $1.0M base salary, a 150% target bonus, and a $7.0M target equity award, with 60% in performance stock units. The large PSU weighting ties most of the equity value to multi-year performance targets, which aligns the new CFO with long-term shareholder returns. The absence of a sign-on award means no one-time buyout or make-whole payment was required.

Does the 2025 guidance reaffirmation change the investment case?

The statement that CVS expects to meet or exceed its 2025 guidance is a modestly positive signal, since it reflects year-to-date results through February. However, the company explicitly said first-quarter closing procedures were incomplete and that the full-year outlook could change. Investors should wait for Q1 results before treating the guidance as firm.

Will Tom Cowhey's departure affect the company's operations going forward?

Cowhey will remain employed as Strategic Advisor to the CEO and will help with the transition until his departure date, which is not yet set. This overlap, along with Newman's CFO Designate period starting April 21, should limit disruption in finance operations and reporting. The overlap period is a point to monitor, since the exact end date of Cowhey's involvement has not been disclosed.

CVS 8-K: Leadership Changes & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed April 8, 2025. Cited figures are marked; the original filing is the authoritative source.

CVS Health announced on April 8, 2025 a planned change in its finance leadership.

Brian O. Newman, currently CFO of United Parcel Service and a board member of Colgate-Palmolive, was named Executive Vice President and Chief Financial Officer. He becomes CFO Designate on April 21, 2025 and assumes the CFO role effective May 12, 2025.

Thomas F. Cowhey, the incumbent CFO, steps down from that role on the same May 12 date and will remain with the company as Strategic Advisor to CEO David Joyner until an undetermined departure date. For investors, the key items are the orderly handover of the CFO seat, Newman's compensation package (a $1.0 million^a base salary, a 150% target bonus, and a $7.0 million target annual equity award, with no sign-on award), and an 18-month non-compete and non-solicit covenant.

The filing also discloses a second leadership change. Amy L. Compton-Phillips, M.D., formerly chief physician executive at Press Ganey and earlier president and chief clinical officer at Providence Health & Services, becomes Executive Vice President and Chief Medical Officer effective May 19, 2025.

She succeeds Sreekanth K. Chaguturu, M.D., who moved to President of Health Care Delivery in November 2024. In a Regulation FD disclosure, CVS said that year-to-date results through February put it on track to meet or exceed its previously issued 2025 full-year guidance.

The company cautioned that first-quarter financial closing procedures were not complete, so full-year expectations could still change. Investors should treat the guidance language as preliminary until first-quarter results are released.

02—Key points

Key Highlights

CFO transition: Brian O. Newman (ex-UPS CFO, 26 years at PepsiCo) succeeds Tom Cowhey as EVP and CFO; he is CFO Designate from April 21, 2025 and CFO effective May 12, 2025.
Cowhey remains with CVS as Strategic Advisor to CEO David Joyner during the transition, with his final departure date not yet determined.
Newman compensation: $1.0M base salary, 150% target annual bonus (pro-rated for 2025), and $7.0M target annual equity award (60% PSUs, 20% RSUs, 20% options); no sign-on award.
Newman signed the customary change-in-control agreement and a restrictive covenant with 18-month non-compete and non-solicit provisions.
New Chief Medical Officer: Amy L. Compton-Phillips, M.D., becomes EVP and CMO effective May 19, 2025, reporting to CEO David Joyner; Sreekanth Chaguturu had held the role before moving to President, Health Care Delivery.
2025 guidance: based on results through February, CVS expects to meet or exceed previously issued full-year 2025 guidance, but Q1 financial close is not complete and the outlook could change.
No related-party transactions or family relationships were disclosed for Newman, and no sign-on or other arrangements beyond those described were reported.

03—Questions

Frequently Asked Questions

Why is CVS changing its CFO, and is this a sign of financial trouble?
The filing does not give a reason for the change beyond a planned transition. CEO David Joyner praised Cowhey's leadership, and the company's statement on 2025 results (meeting or exceeding guidance based on year-to-date results) does not suggest distress. Still, investors may want to watch how the handover affects the timing and tone of financial reporting.
What is Brian Newman's background and why does it matter?
Newman was CFO of UPS from September 2019 to May 2024 and spent 26 years at PepsiCo in finance, strategy, business development, and global operations roles, including chief strategy officer. His experience running a large, complex global company's finances is relevant to CVS's scale and its push to deliver better health care outcomes. He also sits on the board and audit committee of Colgate-Palmolive.
How does Newman's compensation compare to the outgoing structure, and what incentives does it create?
The package includes a $1.0M base salary, a 150% target bonus, and a $7.0M target equity award, with 60% in performance stock units. The large PSU weighting ties most of the equity value to multi-year performance targets, which aligns the new CFO with long-term shareholder returns. The absence of a sign-on award means no one-time buyout or make-whole payment was required.
Does the 2025 guidance reaffirmation change the investment case?
The statement that CVS expects to meet or exceed its 2025 guidance is a modestly positive signal, since it reflects year-to-date results through February. However, the company explicitly said first-quarter closing procedures were incomplete and that the full-year outlook could change. Investors should wait for Q1 results before treating the guidance as firm.
Will Tom Cowhey's departure affect the company's operations going forward?
Cowhey will remain employed as Strategic Advisor to the CEO and will help with the transition until his departure date, which is not yet set. This overlap, along with Newman's CFO Designate period starting April 21, should limit disruption in finance operations and reporting. The overlap period is a point to monitor, since the exact end date of Cowhey's involvement has not been disclosed.

04—Continue

← View all 8-K filings